Our groundbreaking label-free technologies enable you to detect and identify the clinical power of, and weaknesses in, your compound from early-stage pre-clinical R&D through to clinical trials. Inoviem, a bioanalytical Contract Research Organization (CRO), enables drug developers to gain higher precision in the understanding of a compound’s clinical Mode of Action (MoA), so that a drug candidate can move rapidly to clinical trials. Inoviem’s expertise in drug-target interaction analysis is based on its groundbreaking NPOT® and PIMS® label-free technologies. These are the world’s first label-free technologies to decipher the native clinical agent’s proteins and nucleic acids within a physiological environment i.e. directly on non-modified human tissue. This achievement distinguishes Inoviem as a leader in an approach that offers clients new dimensions in identifying the therapeutic effect of pharmacological agents. Applications: - Understand the mode of action of your compound - Validate targets in the study model - Choose the compound for development - Stratify different patient groups - Identify secondary targets - Validate target in targeted organism - Define the indication - Identify biomarkers